Artal Group’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

Artal Group’s Portfolio CLCD Stock Details CLCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-5,575	Closed	-$203K	–	114
2016 Q4	$203K	Sell	5,575 -50,000	-90%	-$1.77M	﹤0.01%	91
2016 Q3	$2.12M	Buy	55,575 +50,000	+897%	+$739K	0.04%	83
2016 Q2	$46K	Hold	5,575	–	–	﹤0.01%	69
2016 Q1	$35K	Hold	5,575	–	–	﹤0.01%	60
2015 Q4	$47K	Hold	5,575	–	–	﹤0.01%	80
2015 Q3	$22K	Hold	5,575	–	–	﹤0.01%	76
2015 Q2	$50K	Buy	+5,575	New	+$47.8K	﹤0.01%	70

Other funds holding CLCD

FPF

FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Artal Group's CLCD Position: Q1 2017 in Review

Artal Group sold out of CoLucid Pharmaceuticals, Inc. (CLCD) in Q1 2017, closing a stake of 5,575 shares — an estimated $203K sold.

Artal Group first reported a position in CLCD in Q2 2015 and held it in 7 quarters. The position peaked at $2.12M in Q3 2016. 1 fund tracked by Wall St. Rank holds CLCD as of Q1 2017.

Artal Group reported no remaining CoLucid Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Artal Group sold 5,575 CoLucid Pharmaceuticals, Inc. shares in Q1 2017, an estimated $203K.
Artal Group first reported a position in CoLucid Pharmaceuticals, Inc. in Q2 2015 and held it in 7 quarters.
Artal Group's CoLucid Pharmaceuticals, Inc. position peaked at $2.12M in Q3 2016.
1 fund tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q1 2017.

Based on Artal Group's 13F filing for Q1 2017, filed 15 May 2017.